Oral LNAD+ Rapidly Elevates Intracellular NAD and Metabolic Flux Without Elevating Circulating NAD: Evidence from a Randomized Controlled Trial

Sergey A. Kornilov[1,2,3], Waylon J. Hastings[2,4,5], Lynne Fahey McGrath[2], Michael Leitz-Langan[2], Andrew T. Magis[1,6], Steve M. Coppess[6], & Wendy Komac[2]

1. Institute for Systems Biology, Seattle WA, United States
2. Bryleos, Johnson City TN, United States
3. Biostochastics, Seattle WA, United States
4. Department of Nutrition, Texas A&M University, College Station TX, United States
5. Institute for Advancing Health Through Agriculture, College Station TX, United States
6. ISB BioAnalytica Inc., Seattle WA, United States

Corresponding Author: Wendy Komac
Email: wendy.komac@bryleos.com

Keywords: NAD+; clinical trial; intracellular bioavailability; metabolic flux; aging; nicotinamide adenine dinucleotide

ABSTRACT

Declines in nicotinamide adenine dinucleotide (NAD+) are linked to metabolic stress accompanying

aging and disease. While precursor-based approaches elevate systemic NAD, their clinical translation

can be constrained by biosynthetic bottlenecks and first-pass metabolism. RENEWAL-NAD+

(ClinicalTrials.gov NCT07336836; retrospectively registered 01/04/2026) was a double-blind,

randomized, placebo-controlled Phase 0/1b trial in healthy adults aged 45–75 years (60 randomized;

primary analysis n=50) evaluating 5 days of oral LathMized® NAD+ (LNAD+), a physicochemically

modulated formulation that alters the supramolecular organization and solution behavior of NAD+ while

preserving its native molecular structure. The primary endpoints were change in intracellular NAD

(icNAD), measured in whole blood, and circulating NAD (cirNAD), measured in separated plasma,

relative to baseline. LNAD+ produced a rapid and pronounced increase in icNAD, with a 53% elevation

versus placebo at Day 6 ($p=5.48e^{-14}$; Hedges' g=3.66), while cirNAD was unchanged (p=0.60),

demonstrating compartment-selective augmentation. Plasma NAD catabolites increased substantially (1-

methyl-nicotinamide, MeNAM $p=5.39e^{-13}$; N1-methyl-2-pyridone-5-carboxamide, 2PY $p=2.95e^{-16}$),

consistent with downstream engagement of NAD metabolic flux. Exploratory analyses identified non-

overlapping correlates for the two compartments (cirNAD tracking inflammatory and metabolic

markers, icNAD tracking red blood cell indices and NAM). Treatment was very well tolerated: symptom

incidence was comparable between groups (p=0.68), only one mild adverse event (nausea, Grade 1)

occurred in the LNAD+ arm, and no secondary clinical, vital-sign, wellbeing, or wearable-derived

endpoint survived multiplicity correction. These data demonstrate rapid intracellular NAD augmentation

after oral LNAD+ dosing with pharmacodynamic evidence of downstream metabolism, compartment-

specific physiological signatures, and a favorable short-term safety profile, with exploratory multi-omic

analyses ongoing.

<u>INTRODUCTION</u>

Nicotinamide adenine dinucleotide (NAD+) is one of the most fundamental and evolutionarily

conserved molecules in cellular metabolism. It serves dual roles as a coenzyme in over 500 enzymatic

reactions and is a consumed substrate for several families of regulatory enzymes (1, 2). This pyridine

nucleotide, discovered over a century ago by Harden and Young, is now recognized as a master

metabolic regulator whose availability directly influences cellular energetics and organismal healthspan

(3, 4). Thus, the importance of NAD+ in human physiology derives from its central role in bioenergetic

pathways and extends to its recently described roles in epigenetic and post-translational regulation,

circadian rhythm control, and intercellular communication (5, 6).

The centrality of NAD+ to the biology of aging has been reinforced by its mechanistic

intersection with multiple hallmarks of aging (7, 8). As noted above, NAD+ serves as a co-substrate for

enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and the cyclic ADP-

ribose hydrolase CD38. Each of these consumes NAD+ stoichiometrically during catalysis. Age-related

upregulation of CD38 expression is linked to chronic low-grade inflammation ("inflammaging") and

senescence-associated secretory phenotype (SASP) signaling, and is thought to be a strong driver of age-

dependent tissue NAD+ depletion (9), creating a feed-forward cycle in which declining NAD+ impairs

enzymes responsible for maintaining genomic stability (PARP1), mitochondrial quality control

(SIRT1/SIRT3), and metabolic homeostasis (10, 11). This mechanistic convergence positions NAD+

repletion as a high-leverage point for interventional geroscience, consistent with a broad inter-tissue

NAD regulatory principles described in the NAD World 3.0 model by Imai et al. (12).

Aging-accompanying immunosenescence is characterized by reduced adaptive immune reserve,

impaired vaccine responsiveness, and altered leukocyte homeostasis. These phenotypes are tightly

coupled to cellular bioenergetics and NAD+-dependent signaling. Because CD38 expression is enriched

in immune compartments and increases with age, age-associated NAD+ depletion may

disproportionately constrain immune metabolic fitness in older adults (13, 14). Recent evidence indeed

suggests that NAD+ depletion in aged CD8+ T cells drives mitochondrial dysfunction and loss of stem-

like properties. Importantly, these effects can be rescued via NAD+ repletion without inflammatory

activation (13).

Given NAD+'s central role in cellular metabolism and regulation, alterations in NAD+

homeostasis are closely linked to human health and disease. Growing evidence from human studies and

animal models suggests that tissue NAD+ levels decline with age, with reductions of 50–65%

documented in multiple tissues by the eighth decade of life (15, 16). The clinical manifestations of

NAD+ decline have been documented across diverse tissues and conditions, where plasma metabolomic

analyses show dysregulation in both healthy aging and disease (17). Importantly, brain NAD+ levels

measured *in vivo* also demonstrate significant age-related decline, with vulnerability in regions affected

by neurodegenerative diseases such as Parkinson's Disease and Alzheimer's Disease (18-20). Skeletal

muscle (a tissue with high metabolic demands and limited regenerative capacity in aging) exhibits

pronounced NAD+ depletion in age-related sarcopenia and is hypothesized to contribute to both

impaired mitochondrial function and reduced exercise capacity in aging (21). The clinical relevance of

these findings encompasses a broad spectrum of age-related diseases where NAD+ depletion represents

both a biomarker and pathogenic factor.

The recognition that NAD+ depletion represents a modifiable risk factor for disease has

generated considerable interest in therapeutic strategies to restore NAD+ homeostasis. Current

approaches predominantly rely on administration of NAD+ precursors including nicotinamide (NAM),

nicotinic acid (NA), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). While

86 precursor-based strategies have demonstrated efficacy in elevating systemic NAD+ levels in human

87 trials, fundamental limitations constrain their therapeutic efficacy and clinical translation.

88   Bioavailability cascades create sequential barriers that reduce effective delivery of oral NAD+

89 precursors to target tissues. Recent studies found that the gut microbiome plays a dominant and

90 previously unappreciated role in precursor metabolism, with bacterial deamidases converting over 95%

91 of orally administered NMN and 80–85% of NR to deamidated forms before systemic absorption (22,

92 23). Following initial absorption, hepatic first-pass metabolism presents the next barrier, with the liver

93 expressing high levels of nicotinamide N-methyltransferase that rapidly clears NAM from circulation

94 through methylation, creating a metabolic burden and potential depletion of S-adenosylmethionine pools

95 (24).

96   Even when precursors successfully navigate metabolic barriers, tissue-specific heterogeneity in

97 NAD+ responses impose additional constraints. Most human studies measure NAD+ in a single

98 biological compartment, with the majority measuring whole-blood concentrations. While blood NAD+

99 levels reliably increase with precursor administration (ranging from approximately 22–370% with NR

100 and 11–60% with NMN in clinical trials), translation to metabolically relevant tissues shows marked

101 variability (25, 26). The disconnect between systemic and tissue NAD+ elevation is exemplified by

102 studies that demonstrate high (e.g., +90%) blood NAD+ increases without corresponding muscle

103 elevation in metabolically compromised individuals, suggesting factors such as transporter expression,

104 local enzyme capacity, and tissue-specific NAD+ consumption regulate the therapeutic efficacy of

105 precursor-based NAD+ repletion (27-30).

106   Considering these limitations, direct NAD+ administration has long been recognized as

107 theoretically ideal but practically challenging due to the molecule's physicochemical properties.

108 Evidence reviewed in a recent report prepared by the University of Maryland regarding inclusion of

NAD+ in the 503B Bulks List suggested that current NAD formulations were susceptible to degradation

and not stable as oral formulations. Nonetheless, it is overall supportive of positive therapeutic effects in

human studies that administered exogenous NAD+ or NADH in patients with fatigue, Parkinson's

Disease, and addiction (31). NAD+ has a molecular weight of 663.43 Daltons, exceeding typical

absorption thresholds, multiple negatively charged phosphate groups confer extreme hydrophilicity at

physiological pH ($logP = -11.6$); its lability directly translates into poor shelf stability; and its

susceptibility to rapid enzymatic degradation in the gastrointestinal tract limits half-life to less than five

minutes (32, 33). These characteristics have historically led to oral NAD+ bioavailability estimates

placing below 2%, thereby removing this route as a viable therapeutic option for NAD+ repletion.

Intravenous (IV) NAD+ administration is aimed at enhancing bioavailability but presents its own

significant limitations. Hawkins et al. demonstrated that 500 mg intravenous NAD+ produced only a 2%

increase in whole blood NAD+ at 24 hours, levels which were substantially inferior to both IV and even

orally administered NR (34). Moreover, the rapid systemic clearance (half-life ~1.7 hours), requirement

for prolonged infusions, substantial incidence of adverse events including flushing and chest discomfort,

and impracticality for chronic administration limit the utility of IV NAD+.

The development of LathMized® NAD+ (LNAD+) therefore represents a systematic response to

the biochemical barriers limiting the effective oral administration of NAD+. The proprietary LathMize®

platform was developed by Bryleos (Johnson City, TN) as a green chemistry and physical pharmacy

process enabling solventless manufacturing of fragile endogenous molecules without altering their

chemical identity. LNAD+ was engineered to enhance physicochemical stability and support systemic

and intracellular availability following oral administration.

The RENEWAL-NAD+ study presented in this report was motivated by the dearth of evidence

on oral NAD+ bioavailability and limited characterization of the mechanisms of action of NAD+

repletion. This study incorporated compartmentalized measurements of NAD+ in plasma (circulating

NAD, cirNAD) and in whole blood (intracellular NAD, icNAD), allowing assessment of the relationship

between systemic NAD+ pools and intracellular NAD+ dynamics. The majority of human NAD+

supplementation studies report whole-blood NAD+ concentrations, which predominantly reflect

erythrocyte NAD+ pools without distinguishing between circulating and cell-associated fractions. This

lack of compartmental resolution has been recognized as a barrier to interpreting the translational

significance of NAD+-boosting interventions (35, 36), particularly relevant in aging research, where

interventions may differentially affect extracellular pools, erythrocytes, and immune cell compartments,

complicating cross-trial comparisons that rely solely on whole-blood measurements. In this study,

icNAD reflects a whole-blood, predominantly erythrocyte derived intracellular component rather than a

tissue or a measure specific to peripheral mononuclear cells (PBMCs).

The present first-in-humans study was therefore designed as a key translational step in

establishing the safety, tolerability, and bioavailability of LNAD+ in healthy aging adults. The study had

three primary objectives: (1) to determine whether oral LNAD+ administration increases intracellular

NAD+ concentrations as measured in the red blood cells in whole blood vs. circulating NAD+ as

measured in separated plasma alone; (2) to characterize the metabolic fate of administered NAD+

through quantification of downstream catabolites in plasma; and (3) to establish the safety profile of

short-term oral NAD+ supplementation across clinical laboratory panels, vital signs, patient-reported

outcomes, and wearable-derived activity and sleep measures.

METHODS

Study Design, Randomization, and Intervention

RENEWAL-NAD+ was a double-blind, randomized, placebo-controlled study

(ClinicalTrials.gov NCT07336836; retrospectively registered 01/04/2026) to evaluate the safety,

tolerability, and pharmacodynamic effects of five days of oral LNAD+ in healthy adults aged 45 to 75

years. ISB BioAnalytica Inc. (Seattle, WA) functioned as the Contract Research Organization,

responsible for study design, implementation, and operational oversight in accordance with ICH GCP

guidelines. The Institute for Systems Biology (ISB) provided scientific collaboration and bioanalytical

expertise. The trial was retrospectively registered on ClinicalTrials.gov (NCT07336836) due to

administrative delay; primary and secondary endpoints were specified in the statistical analysis plan

prior to database lock and unblinding.

Inclusion criteria required participants to abstain from confounding supplements for a seven-day

washout period. Participants had to be non-pregnant with no history of chronic or acute infections within

the last two months and have BMI < 35 kg/m^2. Additional exclusion criteria included current cancer or

hematologic conditions, Type I or Type II diabetes, inflammatory bowel disease, autoimmune disorders,

and use of systemic anti-inflammatory or immunosuppressive medications, with the exception of

NSAIDs and acetaminophen.

Treatment allocation into LNAD+ and placebo arms was performed at enrollment using stratified

a priori blocked randomization schemes. Randomization schemes were derived for males and females

separately using varying block lengths (between K = 2 and K = 4) using R package *blockrand* (v.1.5). If

participants failed the pre-screening or contact was lost prior to the initiation of the study protocol, new

participants were randomized into the freed slot. Biological sex was therefore always included in

statistical analysis as a covariate due to stratification. Overall, the study recruited 76 individuals of

which 60 were enrolled, randomized to treatment, received study kits, and initiated the protocol; 51

participants completed the washout period, received at least one treatment dose, and provided at least

one on- or post-treatment blood draw (N = 23 in LNAD+; N = 28 in the placebo group; see

Supplementary Figure 1 & Supplementary Table 1).

LNAD+ is an oral powder that was supplied by BioNADRx d.b.a Bryleos in opaque plastic

bottles with a masked label. NAD+ constituted 50% of the total mass of powder, with the remainder

being an inactive filler of polyethylene glycol (PEG), a widely used pharmaceutical excipient with a

well-established safety profile; it is generally considered biologically inert, minimally absorbed when

administered orally, and primarily associated with mild, transient gastrointestinal adverse effects at

higher doses (37). Additional orthogonal physicochemical characterization of the LNAD□ formulation

was conducted using complementary analytical approaches to assess elemental composition, molecular

features, and solid-state structure. These analyses confirmed compositional consistency, molecular

identity, and distinct structural attributes of the formulation. Detailed methods and results are not

disclosed due to proprietary considerations. Placebo powder contained only PEG as an inactive

ingredient (100% by mass).

Following a 7-day washout period, participants were administered 2000 mg LNAD+ or placebo

for five days following a QID schedule, with four 500 mg daily doses spread approximately 3–4 hours

apart within a 10–16-hour window. On Days 2 and 3 an additional dose of 500 mg was taken at

nighttime. Treatments were delivered by oral administration as a swish-and-swallow protocol.

Blood Collection

Venous blood specimens (2–4 mL) were collected into K□-EDTA Vacutainer® tubes (BD

Vacutainer®, Franklin Lakes, NJ) by certified phlebotomists during home visits. Samples intended for

NAD+ measurement were immediately placed on ice packs within insulated containers and shipped

overnight to Jinfiniti's facility under cold-chain conditions (2–8°C), with transit times limited to 24–36

hours. Upon receipt, specimens were logged, inspected for hemolysis, and stored pending immediate

processing. Additional blood samples received at ISB were processed in a BSL-2 facility to isolate

plasma, aliquoted, frozen, and biobanked for storage and further processing. Two baseline blood

samples were collected during the one-week washout period 3–4 days and 1–2 days prior to study onset.

On-protocol blood draws were collected on Day 4 (after 3 days of treatment) and on Day 6 (one day

after the final LNAD+ dose). The blood draw on Day 4 corresponds to a cumulative total of ~14 doses

(500mg each); the final blood draw on Day 6 is taken after the last dose for cumulative intake of ~22

doses at 500mg each or 11g total NAD+ administered.

Primary Endpoints: Intracellular and Circulating NAD+

Peripheral venous blood samples were analyzed for circulating and intracellular NAD by Jinfiniti

Precision Medicine (Augusta, GA, USA), a laboratory specializing in NAD+ quantification that

subsequently attained CLIA certification. Intracellular NAD (icNAD) was quantified in the whole blood.

Half of the blood was centrifuged to separate plasma from the cellular fraction and used to measure

circulating NAD (cirNAD). The distinction between these compartments is methodologically important:

cirNAD reflects extracellular NAD+ pools, while icNAD predominantly reflects erythrocyte NAD+

content, providing a measure of cellular NAD+ status.

The Jinfiniti assay employs a proprietary enzymatic cycling assay to generate a colorimetric

signal proportional to total NAD (NAD+ + NADH) concentration. The assay demonstrated an intra-

assay coefficient of variation (CV) of 3.1% based on duplicate measurements within single runs

(provided by Jinfiniti), with a linearity of 0.997 in the range of 0–120 μM and a lower limit of

quantification of 46 nM. In the RENEWAL-NAD+ study, we directly estimated test-retest reliability

across two baseline timepoints at $r = 0.97$ ($p < 0.001$) for icNAD and $r = 0.79$ ($p < 0.001$) for cirNAD,

indicating excellent assay reproducibility.

Safety Endpoints

Safety was evaluated using a combination of vitals, clinical laboratory values, and patient-

reported outcomes. Vital signs included blood pressure and heart rate measured twice at each blood

draw visit and supplemented by wearables data from Fitbit Luxe devices provided to participants, which

also measured activity (steps) and sleep quality (time to fall asleep, sleep duration). Clinical laboratory

values included complete blood count and blood chemistry 24 panels measured in a CLIA-certified

laboratory (LabCorp). Patient-reported adverse event incidence was tabulated at the end of the study

using data volunteered by the participants. Additional patient-reported outcomes included baseline and

daily physical symptoms reported using the Review of Systems questionnaire (RoS), which captures

binary data across 71 symptoms organized into 14 bodily systems, as well as measures of subjective

well-being assessed using the Clinically Useful Anxiety Outcome Scale-Daily version (CUXOS-D) (38),

the Depression, Anxiety, and Stress Scale-21 (DASS-21) (39), and Daily Fatigue Impact Scale (D-FIS)

(40).

Secondary Endpoints: NAD+ Metabolites

Plasma abundance of NAD+ metabolites was assayed by the Metabolon Global Platform and

included measurement of 2PY, nicotinamide (NAM), methylated NAM (MeNAM), trigonelline, and

quinolinate. Frozen aliquots with 200 μL of plasma were shipped on dry ice to Metabolon upon

completion of the study and stored at −80°C prior to metabolomic assaying using previously described

procedures (41). Briefly, after precipitation of proteins in methanol and centrifugation, supernatant

evaporated from each sample was aliquoted into three portions to undergo ultra-high-performance liquid

chromatography/tandem mass spectrometry (UHPLC/MS/MS) for detection of polar as well as nonpolar

metabolites. Metabolite peak detection, quality control, and metabolite identification were performed

using Metabolon's proprietary software, controlling for day-to-day run and between-batch variation

using internal and pooled technical replicate samples, as well as purified standards library. Metabolite

abundance was estimated in Metabolon's proprietary relative abundance units, which represent

normalized peak intensities after Metabolon platform-specific scaling and batch normalization (41).

Additional plasma and blood biospecimens were collected for exploratory multi-omic analyses,

including proteomic and metabolomic profiling; as these analyses were not pre-specified endpoints for

RENWEWAL-NAD+, they are not reported here.

Secondary Endpoints: Oxidative Stress

251   Measures of oxidative stress included serum gamma-glutamyl transferase (GGT) and reactive

252 oxygen metabolites. Serum GGT was measured as part of the standard blood chemistry profile

253 (LabCorp), and reactive oxygen metabolites (O_2, $O_2 \bullet^-$, H_2O_2, $OH\bullet$, & OH^-) were assayed by Jinfiniti.

Secondary Endpoints: Organ Function, Inflammation, and Metabolism

All secondary endpoints of organ function, inflammation, and metabolism were obtained from

complete blood count and blood chemistry panels (LabCorp). Indicators of liver function included levels

of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and total

bilirubin. Indicators of kidney function included serum levels of blood urea nitrogen (BUN), creatinine,

and estimated glomerular filtration rate (eGFR). Metabolism was estimated via fasting glucose, serum

triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Inflammation was

assessed via white blood cell counts, serum levels of high-sensitivity C-reactive protein (hs-CRP), tumor

necrosis factor alpha (TNF-α), and interleukin-6 (IL-6).

Power Calculations

The study sample size was originally determined by a preliminary analysis of statistical power

carried out in GPower 3.0 (42) with the following assumptions: a one-tailed statistical test; Type I error

rate (nominal, without correction for multiple biomarkers) was set at 5% one-sided, to arrive at an

optimistic power estimate given the directional hypotheses testing planned initially. Power analysis was

performed for the F family of tests for repeated measures ANOVAs (3 measurements). Expectations

regarding observed effect sizes were guided by the general considerations of effect size distributions in

biomarker studies as well as conventional categories for Cohen's (1988) f^2 classifying values above 0.10

as small, 0.25 as moderate, and 0.40 as large (43). Cohen's f^2 thresholds were used solely for sample size

estimation in power analyses and are not used for interpretation of study results.

The primary parameter of interest was statistical significance of an interaction term between

treatment Group $\times$ Time or a within-between interaction. At 30 total participants (15 per arm), the study

was projected to attain power of ~80% to detect very large effect sizes (local Cohen's $f > 0.50$).

Increasing the total target sample to 60 (30 per arm) was determined to enable the study to consider

effect sizes in the medium range, with power fluctuating from 50% for $f = 0.25$ to ~80% for $f = 0.35$.

The study anticipated an attrition rate of 20% and was not designed to accommodate corrections for

multiple testing across secondary endpoints. The study targeted N=60.

Statistical Analyses

All analyses were performed in R (version 4.4.2) using a reproducible {targets} pipeline with

computational environment locked via renv. Primary and secondary endpoints were analyzed using

Mixed Models for Repeated Measures (MMRM), implemented via the *mmrm* R package (version

0.3.11), which provides robust inference for longitudinal clinical trial data with missing values under the

missing-at-random (MAR) assumption. The MMRM approach models within-subject correlation

through the residual covariance structure rather than random effects, making it particularly well-suited

for clinical trials with structured visit schedules.

The model was specified as: CHG = BASE + AVISIT $\times$ TRT01A + SEX + AGE + BMIBL +

VITDFL + SEX:AGE + us(AVISIT | USUBJID), where CHG represents the change from baseline,

BASE the baseline value (average of two baseline measurements for clinical data), AVISIT the

categorical visit variable, TRT01A the treatment assignment, and covariates for sex, age, baseline BMI,

and vitamin D supplementation status. An unstructured (US) covariance matrix was specified for the

within-subject residuals, allowing each variance and covariance to be estimated freely. The Kenward–

Roger approximation was employed for denominator degrees of freedom, providing appropriate small-

sample inference. Continuous covariates (age, BMI) were centered at their mean values. Visit-specific

treatment contrasts and p-values were obtained via the *emmeans* R package (v1.10), with two-sided 95%

confidence intervals.

For the primary NAD endpoints, nonparametric bootstrap confidence intervals were

implemented using bias-corrected and accelerated (BCa) methodology with subject-level case

resampling. The pre-specified MMRM was fit to the complete data to obtain the point estimate, then

refitted to bootstrap replicate datasets generated by resampling subjects with replacement. A parallel

jackknife pass (successively leaving out one subject at a time) provided the acceleration correction. To

address multiplicity across clinical laboratory panels, p-values underwent Benjamini–Hochberg false

discovery rate correction within outcome families (e.g., liver function, lipid metabolism, hematology).

For global multiplicity assessment across families, the effective number of independent tests (M_{eff}) was

estimated using the Galwey (44) eigenvalue method applied to a regularized Ledoit–Wolf shrinkage

covariance matrix of test statistics, with Šidák correction applied at the M_{eff}-adjusted significance

threshold. Symptom incidence from the Review of Systems (RoS) questionnaire was analyzed using

binomial generalized linear mixed models (GLMMs) as implemented in glmmTMB, with treatment $\times$

visit interaction as the fixed effect of interest and random intercepts for subjects. Additional details

regarding data processing and quality control are described in **Supplementary Methods** and

Supplementary Tables 2-3.

Analyses were conducted on two overlapping analysis sets: the full intent-to-treat population (N

= 51) and a primary analysis excluding one participant in the placebo group (N = 50) whose icNAD

levels demonstrated a substantial decline after study initiation, consistent with recent discontinuation of

B-vitamin supplements (a protocol-endorsed exclusion criterion). This exclusion was made after

consultation with a reviewer after the unblinding of treatment assignment. Results were materially

unchanged between the two analysis sets, and the primary analysis cohort (N = 50) is presented

throughout. Alignment between analyses within the full intent-to-treat population (N = 51) and analysis

cohort (N = 50) are presented in **Supplementary Figure 2**. Effect sizes for results are interpreted in the

context of conventional categories for Hedge's g classifying values above 0.20 as small, 0.50 as

moderate, and 0.80 as large (45).

Changes to Trial Protocol-Statistical Analysis Plan

Five methodological refinements were implemented following the initial protocol and the

statistical analysis plan (SAP). First, an additional baseline blood draw was incorporated to enable

derivation of more reliable baseline measurements, thereby increasing statistical power for within-

subject change-from-baseline analyses.

Second, the primary analytical framework was updated from mixed ANOVA/ANCOVA to

MMRM. This transition reflects current best practice in longitudinal clinical trial analysis, as

recommended by regulatory guidance (ICH E9(R1)), and offers superior handling of missing data under

the MAR assumption, explicit modeling of within-subject correlation structures through the unstructured

covariance specification, and direct baseline covariate adjustment. The MMRM approach is more

conservative than the originally planned ANOVA in that it makes fewer distributional assumptions

about the correlation structure while providing narrower confidence intervals through efficient use of all

available data.

Third, the SAP evolved from one-tailed hypothesis testing to two-sided tests with corresponding

two-sided 95% confidence intervals. This more conservative inferential standard was adopted to align

with conventional reporting norms; all reported treatment effects (primary endpoints) remain highly

significant under this more stringent criterion. Fourth, for the primary endpoints, nonparametric bias-

corrected and accelerated (BCa) bootstrap confidence intervals were implemented using subject-level

case resampling to complement parametric MMRM inference, providing robust evidence of treatment

effects without reliance on distributional assumptions. Fifth, blood draw windows were expanded to

allow collection on variable days, including expanding baseline blood draws 3-4 days and 1-2 days prior

to study onset, as well as adapting on-protocol blood draws for one participant to be on Day 3 and Day 5

instead of Day 4 (on protocol draw #1) and Day 6 (one day following final LNAD+ dose).

Collectively, these refinements were judged to increase the conservatism of the analysis and

inference relative to the original protocol and SAP. The primary results are robust to the choice of

analytical framework: MMRM, the originally planned ANOVA, and nonparametric bootstrap all yield

concordant conclusions regarding the primary endpoint.

RESULTS

Sample Demographics

Study demographics are presented in **Table 1**. The LNAD+ and the placebo arms did not differ

at baseline with respect to any of the examined characteristics including clinical laboratory test values,

frequency of reporting of medical conditions, or medications usage (all p's > 0.05). In addition to self-

reported data, plasma metabolomics were utilized to determine tobacco usage or nicotine exposure (i.e.,

smoking status). Tobacco metabolites were only detected in two participants in the placebo group; both

were retained in analyses.

Table 1. Baseline demographics and characteristics.

Category	Characteristic	LNAD+ (N=23)	Placebo (N=27)
	N	23	27
Age (years)	range	48.0 – 72.0	46.0 – 72.0
	mean (SD)	57.3 (7.3)	59.3 (7.2)
Sex, n (%)	Female	12 (52.2%)	14 (51.9%)
	Male	11 (47.8%)	13 (48.1%)
	Postmenopausal	1	2

Category	Characteristic	LNAD+ (N=23)	Placebo (N=27)
Race, n (%)	White	17 (73.9%)	25 (92.6%)
	Asian	2 (8.7%)	1 (3.7%)
	Black or African American	0 (0.0%)	1 (3.7%)
	Multiracial	4 (17.4%)	0 (0.0%)
	Other race	0 (0.0%)	0 (0.0%)
Ethnicity, n (%)	Not Hispanic or Latino	19 (82.6%)	24 (88.9%)
	Hispanic or Latino	2 (8.7%)	1 (3.7%)
	Other/Unknown ethnicity	2 (8.7%)	2 (7.4%)
Medical history, n	Depression	6	4
	Anxiety	3	5
	Hypertension	4	4
	Insomnia	3	2
	Sleep apnea	2	2
	Hyperlipidemia	1	2
	Hypothyroidism	2	1
	Heart attack	1	0
Baseline vitals	range	19.6 – 34.5	19.4 – 33.1
	mean (SD)	25.1 (4.1)	24.9 (3.0)
	BMI > 25	11	10
	BMI > 30	2	2
Waist circumference (in)	Waist circumference, mean (SD)	36.1 (5.0)	35.4 (4.5)
Systolic BP (mmHg)	range	99.0 – 170.2	98.5 – 168.2
	mean (SD)	131.1 (20.1)	125.7 (16.6)
Diastolic BP (mmHg)	range	65.0 – 116.5	66.8 – 104.2
	mean (SD)	83.2 (12.1)	81.6 (9.2)
Heart rate (bpm)	range	52.5 – 84.2	53.2 – 91.0
	mean (SD)	70.2 (9.3)	70.1 (10.6)
	Smoking (metabolite-based)	0	2
Baseline NAD+	Baseline icNAD (uM)	28.8 (4.7)	28.9 (4.8)
	Baseline cirNAD (nM)	390.2 (94.5)	392.8 (105.9)
	Vitamin D supplementation	14 (60.9%)	8 (29.6%)

Values are mean (SD) for continuous variables and n (%) for categorical variables. Continuous: age, BMI, weight, height,
systolic BP, diastolic BP, heart rate. Categorical: sex, race (White, Asian, Black or African American, Multiracial), ethnicity.
Baseline icNAD (μM) and cirNAD (nM) values averaged across the two pre-treatment blood draws. Groups were well
balanced at randomization. Primary analysis cohort (N = 50).

Primary Endpoints: Intracellular and Circulating NAD+

Participants were compliant with study procedures. Manual verification of paper and/or

electronic dose logs confirmed treatment compliance for 49 out of 51 participants (96%). The study met

its primary endpoint: oral LNAD+ administration resulted in a statistically significant increase in

intracellular NAD (icNAD) concentrations relative to placebo across both on-protocol visits (Day 4:

MMRM estimate 38.2%, 95% CI: 29.1–48.0%, p = 4.11×10^{-12}; Day 6: MMRM estimate 53.0%, 95%

CI: 41.2–65.7%, p = 5.48×10^{-14}; Hedges' g = 3.66).

At Day 6, mean icNAD in the LNAD+ group was 43.5 μM (SD 7.1) compared to 28.2 μM (SD

4.7) in the placebo group, whose levels remained unchanged from baseline (29.0 μM, SD 4.7). A total of

18 out of 23 participants (78.3%) receiving LNAD+ achieved greater than 30% increase in icNAD by

Day 6, with a minimum individual increase of 9.4% (**Figure 1**). The treatment effect was confirmed by

nonparametric BCa bootstrap (bootstrap 95% CI: 11.5–18.0 μM raw difference; 1,000,000 BCa

iterations).

LNAD+ administration did not significantly affect circulating NAD (cirNAD) at either timepoint

(Day 4: $p = 0.43$; Day 6: $p = 0.60$), with plasma NAD concentrations remaining stable in both groups

throughout the study period. Full model results for icNAD and cirNAD are presented in **Supplementary**

Tables 4-5. Bootstrap distributions of treatment effects are presented in **Supplementary Figures 3-6**.

Table 2. Primary endpoint NAD concentrations by treatment group and timepoint.

Analyte	Visit	N (LNAD+)	LNAD+ Mean (SD)	N (Placebo)	Placebo Mean (SD)
cirNAD (nM)	Baseline	23	389.9 (86.2)	27	391.4 (105.1)
	Day 4	23	390.3 (100.2)	27	378.5 (114.5)
	Day 6	22	386.5 (103.2)	26	408.0 (119.5)
icNAD (μM)	Baseline	23	28.7 (4.6)	27	29.0 (4.7)
	Day 4	23	39.1 (5.5)	27	28.4 (4.8)
	Day 6	22	43.5 (7.1)	26	28.2 (4.7)

382   Descriptive statistics (mean, SD) for intracellular NAD (icNAD, μM) and circulating NAD (cirNAD,
383   nM) at Baseline, Day 4, and Day 6 by treatment group. MMRM estimates presented in manuscript text.
384

385
Figure 1. Study design and primary NAD+ endpoints. (A) Intracellular NAD (icNAD, μM) measured in whole blood at
Baseline 1, Baseline 2, Day 4, and Day 6 in LNAD+ (blue, n = 23) and Placebo (gray, n = 27) groups. Individual data points
are shown with group means ± SD connected by lines. MMRM treatment contrast p-values annotated at Day 4 and Day 6. (B)
Circulating NAD (cirNAD, nM) measured in plasma. (C) Waterfall plot of individual icNAD percent change from baseline at
Day 6, ranked by magnitude. Blue bars = LNAD+; gray bars = Placebo. Dashed line indicates 30% responder threshold.
Primary analysis cohort (N = 50).
392

393 **Secondary Endpoint: NAD+ Metabolites**

394   LNAD+ administration led to differential, statistically significant increases in plasma abundance

395 of 1-methylnicotinamide (MeNAM; Day 4: p = 6.29×10^{-17}, 551% estimated group difference; Day 6: p

396 = 5.39×10^{-13}, 364%) and N1-methyl-2-pyridone-5-carboxamide (2PY; Day 4: p = 2.55×10^{-19}, 512%;

397 Day 6: p = 2.95×10^{-16}, 368%), compared to placebo (**Figure 2**). Nicotinamide (NAM) showed a

significant treatment effect at Day 4 (p = 0.016, 54% estimated group difference) that was not

maintained at Day 6 (p = 0.30). No significant changes were detected in the plasma abundance of

quinolinate or trigonelline, metabolites associated with the de novo and Preiss–Handler NAD+

biosynthetic pathways, respectively. MeNAM and 2PY remained significant after corrections for

multiple testing. Pre- and post-intervention levels of NAD+ metabolites are reported in **Supplementary**

Table 6.

Figure 2. NAD+ metabolic flux: metabolite pattern consistent with enhanced catabolic processing. (A) Interpretive
pathway schematic showing NAD+ biosynthetic and catabolic routes with measured analytes highlighted. Solid-outlined
nodes indicate metabolites quantified in this trial; thin-outlined nodes are contextual pathway intermediates (not measured).
Warm colors indicate observed treatment-associated increases; gray indicates measured but unchanged. Dashed arrows
indicate uncertain or minor routes. This swish-and-swallow protocol may permit both oral mucosal exposure and
gastrointestinal delivery; however, relative contributions were not determined in this trial; (B) Active catabolic pathway
metabolites: 1-methylnicotinamide (MeNAM), N1-methyl-2-pyridone-5-carboxamide (2PY), and nicotinamide (NAM).
Grouped bar charts showing Metabolon median-normalized relative abundance (mean ± SEM) at Baseline, Day 4, and Day 6
by treatment group (LNAD+ blue, Placebo gray). MMRM p-values annotated. (C) Quinolinate (de novo synthesis
intermediate) and trigonelline (primarily dietary). Primary analysis cohort (N = 50).

Secondary Endpoints: Clinical Laboratory Tests

Total serum bilirubin demonstrated a nominally significant decrease in the LNAD+ group

relative to placebo at Day 6 (MMRM p = 0.019, g = −0.80). Albumin also showed a nominally

significant decrease (p = 0.033, g = −0.77), as did the albumin/globulin (A/G) ratio (p = 0.045, g =

−0.68), with a borderline trend for alkaline phosphatase (p = 0.067, g = −0.63). These correlated hepatic

markers all remained within normal clinical reference ranges, and liver transaminases were unchanged

(ALT: p = 0.80; AST: p = 0.29; GGT: p = 0.86), providing no evidence of hepatocellular injury. These

findings did not survive multiplicity correction (all adjusted p > 0.31).

In the hematological panel, mean corpuscular hemoglobin (MCH; p = 0.031, g = −0.72) and

mean corpuscular hemoglobin concentration (MCHC; p = 0.028, g = −0.73) both registered nominally

significant reductions compared to placebo, at Day 6. These shifts, while statistically detectable, were

small in absolute magnitude and remained within normal clinical ranges.

LNAD+ administration was associated with a nominally significant increase in absolute

lymphocyte count at Day 6 (MMRM estimate = 0.125×10^9/L, Hedges' g = 0.73, p = 0.037), with a

trend in lymphocyte percentage (+4.36 percentage points, g = 0.69, p = 0.053). This effect was not

present at Day 4 (absolute lymphocytes: p = 0.58; percentage: p = 0.33). The lymphocyte increase was

not accompanied by detectable inflammatory activation. Tumor necrosis factor-α (TNF-α) was

unchanged (p = 0.127, g = −0.49), as were interleukin-6 (IL-6; p = 0.866, g = −0.07), high-sensitivity C-

reactive protein (hs-CRP; p = 0.913, g = 0.04), and erythrocyte sedimentation rate (ESR; p = 0.412, g =

−0.28). Total white blood cell count was stable (p = 0.687), and neutrophil percentage showed a

nonsignificant downward trend (g = −0.59, p = 0.093), while neutrophil absolute counts were unchanged

(p = 0.334). The basophil percentage was nominally elevated (g = 0.80, p = 0.016), though this was not

confirmed in absolute counts (p = 0.329), consistent with a proportional shift secondary to differential

changes rather than a true basophil response. The lymphocyte finding did not survive Benjamini–

Hochberg correction within the laboratory outcome family (adjusted p = 0.317).

Finally, with respect to oxidative stress, no treatment-related changes were observed in serum

gamma-glutamyl transferase (GGT; Day 6 p = 0.86) or cumulative levels of reactive oxygen metabolites

(ROM; p = 0.94).

No other clinical laboratory tests displayed nominal statistical significance at Day 6. Renal

function (creatinine: $p = 0.14$; eGFR: $p = 0.25$; BUN: $p = 0.83$), lipid panels (total cholesterol: $p = 0.65$;

LDL: $p = 0.29$; HDL: $p = 0.67$; triglycerides: $p = 0.70$), electrolytes, and glucose metabolism markers

were all unaffected. No nominally significant laboratory findings survived Benjamini–Hochberg

correction within their respective outcome families (all adjusted $p > 0.31$). Pre- and post-intervention

levels of clinical laboratory panels are reported in **Supplementary Table 7**. Complete Day 4 and Day 6

treatment contrasts across all endpoints are presented in **Figure 3**.

450
Figure 3. Safety forest plot: Day 4 and Day 6 MMRM treatment contrasts across endpoints. Hedges' g effect size
estimates (LNAD+ vs Placebo) with 95% confidence intervals for clinical laboratory, vital sign, and wellbeing endpoints,
presented as side-by-side panels: Day 4 (left) and Day 6 (right). Hedges' g computed with small-sample correction factor J =
$1 - 3/[4(n_□ + n_□ - 2) - 1]$; CIs from large-sample variance approximation $SE(g) \approx \sqrt{(1/n_□ + 1/n_□ + g^2/[2(n_□ + n_□)])}$.
Endpoints organized by clinical domain: Vitals, Liver, Proteins, Hematology (RBC, WBC, Other), Inflammation, Kidney,
Lipids, Electrolytes/Metabolic, Oxidative Stress, Wellbeing. Red points indicate nominal $p < 0.05$; gray points indicate $p \geq$
0.05. No secondary findings survived Benjamini–Hochberg correction within their respective outcome families. Vertical line
at zero represents no treatment effect. Primary analysis cohort (N = 50).

Secondary Endpoint: Safety and Tolerability

Systolic blood pressure (SBP) showed a nonsignificant trend toward reduction in the LNAD+

group at Day 6 (MMRM estimate -7.1 mmHg, $g = -0.61$, $p = 0.092$), with no significant changes in

diastolic blood pressure ($p = 0.34$) or heart rate ($p = 0.55$). Body weight and BMI showed nonsignificant

decreasing trends (BMI: $p = 0.092$, $g = -0.58$; weight: $p = 0.163$, $g = -0.48$).

No differential changes were observed in measures of subjective well-being (DASS-21

Depression: $p = 0.82$; DASS-21 Anxiety: $p = 0.97$; DFIS Fatigue: $p = 0.19$; CUXOS Anxiety: $p = 0.71$).

DASS-21 Stress showed a nominally significant improvement at Day 4 ($p = 0.0435$) that did not persist

to Day 6 ($p = 0.468$). Wearable-derived activity endpoints showed nominal shifts toward higher activity

and lower sedentary time (e.g., very active minutes increased and sedentary minutes decreased at Day

6), but no wearable endpoint remained significant after hierarchical false discovery rate correction; sleep

metrics were unchanged. Full results of wearable endpoints are presented in **Supplementary Table 8**.

Only one treatment-emergent adverse event was recorded: mild nausea (Grade 1, CTCAE v5.0)

in a single participant in the LNAD+ arm on Day 2, resolving within 24 hours after discontinuation. The

overall on-protocol symptom burden, assessed via a comprehensive 71-item Review of Systems

questionnaire, was comparable between groups (LNAD+ 2.92% vs Placebo 2.40% symptom-day

incidence; GLMM $p = 0.68$). **Table 3** and **Table 4** present key descriptives for adverse events and

symptom self-reports, and clinical / vital sign endpoints with nominal $p < 0.10$ at Day 6, respectively. A

detailed summary of ROS symptom reports is presented in **Supplementary Table 9**. Full results of ROS

GLMM analyses are presented in **Supplementary Table 10** and **Supplementary Figure 7**.

Table 3. Treatment-emergent adverse events and Review of Systems symptom burden.

	LNAD+ (N=23)	Placebo (N=27)
AEs		
Participants with ≥1 TEAE, n (%)	1 (4.3%)	0 (0%)

	LNAD+ (N=23)	Placebo (N=27)
AEs		
Total TEAEs, n	1	0
Grade 1 (mild)	1 (nausea)	0
Grade ≥2	0	0
Serious AEs	0	0
Discontinuations due to AE	1	0
ROS		
RoS symptom rate (on-protocol)	2.84%	2.38%
RoS GLMM p-value		0.81

481 AE – Adverse Events. Treatment-emergent adverse events and Review of Systems symptom burden. TEAE = treatment-
482 emergent adverse event; RoS = Review of Systems; GLMM = generalized linear mixed model with binomial family.
483
484
485 **Table 4.** Clinical laboratory and vital sign endpoints with nominal p < 0.10 at Day 6

Domain	Analyte	LNAD+ Day 6	Placebo Day 6	Hedges' g	MMRM p	Direction
Hematology (WBC)	Basophils (%)	1.05 (0.49)	0.80 (0.50)	0.80	0.0164	↑ LNAD+
Liver	Bilirubin, Total	0.36 (0.18)	0.46 (0.39)	-0.80	0.0188	↓ LNAD+
Hematology (RBC)	MCHC	33.74 (0.78)	34.07 (0.76)	-0.73	0.0283	↓ LNAD+
Hematology (RBC)	MCH	30.44 (1.28)	30.44 (1.48)	-0.72	0.0307	↓ LNAD+
Proteins	Albumin	4.45 (0.32)	4.52 (0.28)	-0.77	0.0326	↓ LNAD+
Hematology (WBC)	Lymphocytes (abs)	1.89 (0.50)	1.56 (0.47)	0.73	0.0366	↑ LNAD+
Proteins	A/G Ratio	1.91 (0.32)	2.02 (0.31)	-0.68	0.0448	↓ LNAD+
Hematology (WBC)	Lymphocytes (%)	35.00 (7.26)	29.32 (7.30)	0.69	0.0532	↑ LNAD+
Liver	Alk Phosphatase	71.18 (19.98)	75.20 (19.58)	-0.63	0.0674	↓ LNAD+
Vitals	Systolic BP	125.6 (16.1)	126.3 (19.4)	-0.61	0.0921	↓ LNAD+
Vitals	BMI	25.2 (4.0)	25.0 (3.1)	-0.58	0.0924	↓ LNAD+
Hematology (WBC)	Neutrophils (%)	52.32 (8.93)	58.80 (8.76)	-0.59	0.0927	↓ LNAD+

486 Note. Hedges' g computed from MMRM contrasts. No findings survived mEff correction within their respective outcome
487 families. All values remained within clinical reference ranges.

Exploratory Endpoint: Baseline NAD+ Correlation Signatures

Exploratory Spearman rank correlations between baseline NAD+ concentrations and clinical

endpoints tentatively supported compartment-specific signatures that reinforce the rationale for

separating intracellular and circulating NAD+ measurements (**Supplementary Table 11**). Baseline

cirNAD was correlated with tumor necrosis factor-α ($\rho = -0.56$, $p_{BH} = 0.003$), creatinine ($\rho = -0.51$, p_{BH}

$= 0.006$), and positively correlated with HDL cholesterol ($\rho = 0.43$, $p_{BH} = 0.042$), forming a metabolic

and anti-inflammatory signature consistent with CD38-mediated NAD+ consumption in inflammatory

states. Baseline icNAD, by contrast, tracked red blood cell indices - hemoglobin ($\rho = 0.54$, $p_{BH} = 0.003$)

and hematocrit ($\rho = 0.50$, $p_{BH} = 0.006$) - reflecting the measurement compartment (whole blood), and

with the salvage pathway substrate nicotinamide (NAM; $\rho = 0.47$, $p_{BH} = 0.018$), suggesting that

individuals with higher circulating nicotinamide availability maintain higher intracellular NAD+ pools.

DISCUSSION

This double-blind, randomized, placebo-controlled Phase 0/1b trial demonstrated that 5 days of

oral LathMized® NAD+ (LNAD+) produce a rapid, substantial increase in intracellular NAD (icNAD)

measured in whole blood, without a corresponding increase in plasma NAD. In parallel, large increases

in the downstream catabolites 1-methylnicotinamide (MeNAM) and N1-methyl-2-pyridone-5-

carboxamide (2PY) provide pharmacodynamic evidence that administered NAD engages active

metabolic processing pathways: both remained significant after false discovery rate correction. Across

comprehensive clinical laboratory panels, vital signs, patient-reported outcomes, and wearable-derived

activity and sleep measures, LNAD+ was well tolerated over the short dosing period. Secondary clinical

signals observed are reported transparently and should be interpreted as hypothesis-generating.

Cellular Uptake and Absorption Biology

A key question raised by these findings is how exogenous oral NAD+ reaches the intracellular

compartment. We outline several non-exclusive mechanisms that may contribute. First, extracellular

NAD+ can be hydrolyzed by ectoenzymes (CD38, CD73, CD157) to yield nicotinamide (NAM),

nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN), each of which has established

cellular uptake pathways (46, 47). Second, intact NAD+ may cross cell membranes via connexin 43

hemichannels under calcium-regulated conditions (48), though the quantitative contribution of this

pathway *in vivo* at physiological concentrations remains uncertain. Third, recent evidence from head-to-

head precursor trials demonstrates that oral NAD+ precursors undergo extensive gut microbial

conversion (NMN and NR are deamidated to nicotinic acid derivatives before systemic absorption (22,

49), suggesting that the route from oral NAD+ to intracellular NAD+ may involve multiple intermediate

conversions rather than direct intact-molecule uptake. Thus, a plausible alternative explanation is that

orally administered NAD+ is substantially hydrolyzed prior to absorption and functions primarily as a

NAM source. Importantly, recent human data show that oral NAD boosters can enter host NAD

metabolism via distinct, microbiome-dependent routes (e.g., deamidation to nicotinic acid derivatives),

underscoring that "oral NAD booster" to "NAM-only equivalence" is not a safe assumption (22, 49).

The present study cannot determine contributions among these mechanisms as we did not

measure plasma NR, NMN, or nicotinic acid (NA) concentrations, gut microbial conversion, or

erythrocyte transporter expression. However, the empirical finding that the intracellular pool rises while

the plasma pool does not, and that downstream catabolites accumulate, is consistent with efficient

cellular NAD augmentation rather than simple extracellular persistence.

Intracellular NAD+ Elevation and Metabolic Flux

NAD+ metabolism is increasingly conceptualized in terms of dynamic flux rather than static

pool sizes (50). NAD flux represents the dynamic turnover of NAD through biosynthetic, salvage, and

consumption pathways mediated by enzymes such as sirtuins, PARPs, and CD38. Because these

pathways operate within metabolically active cells, intracellular NAD measurements may better reflect

NAD metabolic flux than whole-blood measurements.

The approximately 53% increase in whole blood (primarily RBC-driven) NAD+ observed at Day

6 is commensurate with effects reported for NAD+ precursor interventions of longer duration, where

whole-blood NAD+ increases of 22–100% with nicotinamide riboside (NR) and 11–60% with

nicotinamide mononucleotide (NMN) are typically observed following 2–12 weeks of treatment (25, 49,

51-53). Moreover, the magnitude and rapidity of the icNAD response - detectable at Day 4 (38.2%

group difference) and increasing by Day 6 - suggests efficient delivery of intact or minimally processed

NAD+ to the cellular compartment. Considering a large effect threshold of g>0.80 (45), the effect size

observed (Hedge's g = 3.66) is exceptionally large and indicates virtually no overlap between the

treatment and placebo distributions at Day 6.

The null effect on circulating NAD (cirNAD) is informative as well, as exogenous NAD+ is not

accumulating in the extracellular space but is being taken up by cells or undergoing extracellular

degradation with subsequent cellular uptake of degradation products. This compartment-selective profile

contrasts with intravenous NAD, which elevates circulating NAD transiently. The substantial elevation

of NAD+ catabolites MeNAM and 2PY provides further preliminary pharmacodynamic evidence that

exogenous NAD+ enters active metabolic processing.

Safety and Clinical Implications

LNAD+ demonstrated a favorable safety profile across all assessed domains. The single

treatment-emergent adverse event—mild nausea (Grade 1, CTCAE v5.0)—resolved within 24 hours and

is consistent with the known gastrointestinal tolerability profile of oral PEG-containing or high-dose oral

formulations (37). The overall on-protocol symptom burden, assessed via a 71-item Review of Systems

questionnaire, was comparable between groups (GLMM p = 0.81), providing no evidence of systematic

symptom induction.

The nominally significant increase in absolute lymphocyte count (g = 0.73, p = 0.037) did not

survive multiplicity correction. Even so, the observation that the lymphocyte increase occurred without

concurrent elevation of inflammatory markers TNF-α & CRP is notable, because an inflammatory

etiology (infection, autoimmunity, or nonspecific immune activation) would typically result in

concurrent cytokine and acute-phase reactant elevation. One possible interpretation is that restored

NAD+ availability supports lymphocyte metabolic fitness (viability, homeostatic proliferation, or

resistance to apoptosis) independently of inflammatory signaling. This interpretation is supported by

recent evidence that NAD+ depletion in aged CD8+ T cells drives mitochondrial dysfunction and loss of

stem-like properties, and that NAD+ precursor supplementation rescues these phenotypes without

activating inflammatory pathways (13, 54). The concurrent downward trend in neutrophil percentage (g

$= -0.59$, $p = 0.093$) is compatible with this framing, as a shift in the lymphocyte-to-neutrophil ratio is

associated with reduced systemic inflammatory tone. Separately, nominally significant shifts in MCH (p

$= 0.031$) and MCHC ($p = 0.028$) - RBC-intrinsic indices not influenced by plasma volume - were driven

primarily by placebo-arm increases rather than LNAD+ decreases; these small changes of unclear

clinical significance remained within reference ranges.

Among clinical laboratory parameters, nominally significant decreases in albumin ($p = 0.033$, g

$= -0.77$), A/G ratio ($p = 0.045$, $g = -0.68$), and total bilirubin ($p = 0.019$, $g = -0.80$) were observed in

the LNAD+ group relative to placebo. None survived multiplicity correction. For protein markers

(albumin, A/G ratio), arm-specific trajectories show bidirectional divergence at Day 6: the LNAD+ arm

decreases mildly from baseline while the placebo arm drifts upward. Total bilirubin showed the largest

nominal effect among these markers ($g = -0.80$, $p = 0.019$). Unlike albumin, bilirubin is a heme

degradation catabolite whose clearance depends on hepatic glucuronidation via UGT1A1, the major

bilirubin-glucuronidation enzyme. One hypothesis is that enhanced intracellular NAD+ availability

upregulates UGT1A1 cofactor supply (UDP-glucuronic acid is synthesized through NAD+-dependent

oxidation of UDP-glucose) and/or UGT1A1 expression via the SIRT1–PGC-1α axis, accelerating

bilirubin conjugation. This would represent a pharmacodynamic consequence of NAD+ repletion.

However, this study did not report on conjugated vs. unconjugated bilirubin fractions, UGT1A1 activity,

or hepatic NAD+ status, and the bilirubin decrease could also reflect plasma volume changes, analytic

variability, or chance. Importantly, hepatocellular injury markers were entirely unchanged (ALT: p =

0.80; AST: $p = 0.29$; GGT: $p = 0.86$), and all observed values remained within clinical reference ranges,

providing no evidence of hepatotoxicity. These patterns should be monitored in longer-duration studies

with pre-specified endpoints, including bilirubin fractionation, plasma volume markers, and UGT1A1

genotype/activity to distinguish among these interpretations.

The elevation of MeNAM and 2PY has implications for specific clinical populations. Both

metabolites have been previously identified as potential uremic toxins that accumulate in chronic kidney

disease (CKD), although their role in cardiovascular and renal pathology is under investigation (55).

While the observed increases are in healthy adults with presumably normal renal clearance, future

studies of NAD+ supplementation in renally impaired populations should include systematic monitoring

of these catabolites.

Limitations

Several limitations should be considered when interpreting these findings. The sample size (n =

50 primary analysis; n = 51 full ITT sensitivity set) was sufficient to detect the very large primary

endpoint effect on icNAD but was not powered for smaller secondary effects. Multiple comparisons also

constrain inference for secondary outcomes: across the 70 clinical laboratory, vital sign, and wellbeing

endpoints evaluated in the primary analysis pipeline, the effective number of independent tests was M_{eff}

= 56 (Galwey eigenvalue method with Ledoit–Wolf shrinkage), corresponding to a global Šidák

threshold of $\alpha \approx 0.000926$. Under this global correction, only icNAD and NAD metabolites MeNAM

and 2PY remained statistically significant. Other nominal findings within this endpoint set (e.g.,

lymphocytes, hepatic marker shifts, SBP trend) should be interpreted as hypothesis-generating and

prioritized for replication.

We acknowledge that the 5-day dosing period establishes acute pharmacodynamic proof-of-

concept but cannot address questions of chronic NAD+ homeostasis, potential compensatory

downregulation of endogenous NAD+ biosynthesis, or sustained clinical benefit. The study population

(predominantly White, healthy adults aged 45–75 from a single site in the Pacific Northwest of the

United States) also limits its generalizability. The absence of severely metabolically compromised

participants (e.g., with type 2 diabetes, sarcopenia, or neurodegenerative disease) means the study does

not directly translate to the populations most likely to benefit from NAD+ restoration, where baseline

NAD+ depletion may produce larger treatment effects.

The Jinfiniti assay measures total NAD (NAD+ + NADH) rather than the NAD+/NADH ratio. If

NADH is co-elevated, the functional redox implications would differ from a selective increase in

oxidized NAD+. Future studies should incorporate ratio-specific assays or complementary measures of

NAD+-dependent enzymatic activity to resolve this question.

The analytical approach evolved from the original SAP in five documented respects (see

Methods). The most substantive change (adoption of MMRM over mixed ANOVA) represents a more

conservative analytical framework that is now standard in longitudinal clinical trial analysis. The shift

from one-tailed to two-tailed testing further increases inferential stringency. All primary findings are

robust across the original and updated analytical frameworks, across the full (N = 51) and sensitivity (N

= 50) analysis sets, and across parametric (MMRM) and nonparametric (BCa bootstrap) inference

methods.

Finally, we recognize that measurement of icNAD in the whole blood (dominated by RBCs

rather than PBMCs) has both advantages and limitations for interpreting the biological significance of

the observed increase. Mature erythrocytes have limited NAD+ biosynthetic capacity: they lack nuclei

and mitochondria and therefore cannot perform de novo NAD+ synthesis, relying exclusively on the

NAMPT-NMN-NMNAT3 salvage axis, as demonstrated by studies showing that NMNAT3 deficiency

depletes RBC NAD+ and causes hemolytic anemia (56). Erythrocyte NAD+ concentrations decline with

advancing age in humans (57). Consequently, elevation of RBC NAD+ following oral administration

implies effective delivery of NAD+ (or its immediate metabolites) across the erythrocyte membrane, a

finding with implications for other cell types with similarly constrained biosynthetic capacity. We

acknowledge that generalization of the signal from erythrocytes to metabolically active tissues such as

immune cells, muscle, liver, or brain requires tissue-specific measurements that were beyond the scope

of this study.

Conclusion

RENEWAL-NAD+ was a Phase 0/1b randomized, double-blind, placebo-controlled trial

demonstrating that 5 days of oral LathMized® NAD+ (LNAD+) produces a rapid, substantial increase

in intracellular NAD (icNAD) measured in the whole blood compartment, while circulating NAD

(cirNAD) in plasma remains unchanged. The marked increases in the downstream NAD catabolites 1-

methylnicotinamide (MeNAM) and N1-methyl-2-pyridone-5-carboxamide (2PY) provide

pharmacodynamic evidence of engagement of NAD metabolic flux pathways following oral dosing.

LNAD+ was well tolerated over the short intervention, with no clinically meaningful safety concerns

observed across regular and comprehensive assessment of clinical laboratory tests, vitals, and subjective

indices of well-being. Secondary signals (including a nominal Day 6 lymphocyte increase without

inflammatory marker elevation) did not remain significant after multiplicity correction across the 70

clinical laboratory, vital sign, and wellbeing endpoints analyzed in the primary pipeline and should be

interpreted as hypothesis-generating. Additional exploratory multi-omic profiling of pharmacodynamic

responses to LNAD+ are ongoing and will be reported separately. Together, the findings establish short-

term human intracellular NAD augmentation and downstream metabolic engagement after oral NAD+

administration, supporting longer-duration studies with dose-response characterization, tissue- and cell-

specific NAD measurements, and pre-specified immune and hepatic monitoring endpoints.

ABBREVIATIONS

2PY = N1-methyl-2-pyridone-5-carboxamide; ALP = Alkaline Phosphatase; ALT = Alanine

Transaminase; AST = Aspartate Transaminase; BCa = Bias-Corrected and Accelerated; BMI = Body

Mass Index; BUN = Blood Urea Nitrogen; CD38 = Cluster of Differentiation 38; CI = Confidence

Interval; cirNAD = Circulating/Extracellular NAD; CLIA = Clinical Laboratory Improvement

Amendments; CTCAE = Common Terminology Criteria for Adverse Events; CUXOS-D = Clinically

Useful Anxiety Outcome Scale, Daily Version; CV = Coefficient of Variation; D-FIS = Daily Fatigue

Impact Scale; DASS-21 = Depression, Anxiety, and Stress Scale-21; DBP = Diastolic Blood Pressure;

eGFR = Estimated Glomerular Filtration Rate; ESR = Erythrocyte Sedimentation Rate; GGT = Gamma-

Glutamyl Transferase; GLMM = Generalized Linear Mixed Model; HDL = High-Density Lipoprotein;

hs-CRP = High-Sensitivity C-Reactive Protein; icNAD = Intracellular NAD; IL-6 = Interleukin-6; LDL

= Low-Density Lipoprotein; LNAD+ = LathMized® NAD+; MAR = Missing at Random; MCH = Mean

Corpuscular Hemoglobin; MCHC = Mean Corpuscular Hemoglobin Concentration; MeNAM = 1-

Methylnicotinamide; M_{eff} = Effective Number of Independent Tests; MMRM = Mixed Models for

Repeated Measures; NAD+ = Nicotinamide Adenine Dinucleotide; NAM = Nicotinamide; NMN =

Nicotinamide Mononucleotide; NNMT = Nicotinamide N-Methyltransferase; NR = Nicotinamide

Riboside; PARP = Poly(ADP-ribose) Polymerase; PEG = Polyethylene Glycol; QID = Quarter-in-die

(four times daily); RBC = Red Blood Cell; ROM = Reactive Oxygen Metabolites; RoS = Review of

Systems; SAP = Statistical Analysis Plan; SBP = Systolic Blood Pressure; SIRT = Sirtuin; TNF-α =

Tumor Necrosis Factor Alpha; UGT1A1 = UDP-Glucuronosyltransferase 1A1; US = Unstructured

(covariance); WBC = White Blood Cell Count

AUTHOR CONTRIBUTIONS

Study Design: Sergey A. Kornilov, Andrew Magis, Wendy Komac; *Study Conception*: Wendy Komac;

Sample Acquisition: Steve M. Coppess, Andrew Magis, & Sergey A. Kornilov; *Statistical Analysis*:

Sergey A. Kornilov & Waylon J. Hastings; *Data Interpretation and Manuscript Drafting*: Waylon J.

Hastings, Sergey A. Kornilov, Michael Leitz-Langan, Lynne Fahey McGrath; *Manuscript Critical*

Review: All authors.

ACKNOWLEDGEMENTS

We thank the staff at Institute for Systems Biology and ISB BioAnalytica Inc. for their diligence in

conducting participant screening, recruitment, and study procedures as well as all research participants

who provided their time and resources to complete RENEWAL-NAD+. We wish to extend our sincerest

appreciation to Dr. Mia Nease for her generous contribution of time, expertise, and scientific insight in

guiding the incorporation of multi-omics approaches into the RENEWAL Study design. Her thoughtful

input and collaborative spirit were invaluable to the development of this work.

CONFLICTS OF INTEREST

At the time of the study, SK was an employee of Institute for Systems Biology. SK and WJH hold stock

options in BioNADRx and are paid consultants who received consultancy fees during the preparation of

this manuscript. WK is the CEO of BioNADRx and holds stock options and shares. LFM holds stock

options in BioNADRx and is a Company Advisor. SMC and ATM are founders of ISB BioAnalytica

Inc. SMC is an investor in BioNADRx and holds shares. ML is an investor in BioNADRx and holds

stock options and shares.

ETHICAL STATEMENT

This study, and any subsequent modifications, was reviewed and approved by the Western Institutional

Review Board (now known as WCG-IRB), as defined by Federal Regulatory Guidelines (Ref. Federal

Register Vol. 46, No. 17, January 27, 1981, part 56) and the Office for Protection from Research Risks

Reports: Protection of Human Subjects (Code of Federal Regulations 45 CFR 46). IRB Tracking

Number 20215675. The study was conducted per IRB-approved protocol (10/13/2021, Version 1) with

study code ISBA-101 and study number 1320748. The study was conducted according to the ethical

principles of the Declaration of Helsinki and current Good Clinical Practice guidelines, and in

compliance with federal, state, and local regulatory requirements, including 21 CFR 312, 21 CFR 50,

and 21 CFR 56.

CONSENT

Informed consent was obtained from each participant in an electronic format (e-consent) at enrollment

following pre-screening and pending confirmation with the Study Coordinator. The Study Coordinator

and/or the PI of the study described the study and answered questions about the study goals and the

protocol, as needed. The principles of informed consent followed are described by Federal Regulatory

Guidelines (Federal Register Vol. 46, No. 17, January 27, 1981, part 50) and the Office for Protection

from Research Risks Reports: Protection of Human Subjects (Code of Federal Regulations 45 CFR 46).

The Informed Consent Form was reviewed and approved by Western IRB (now known as WCG IRB) as

part of the protocol submission.

FUNDING

BioNADRx Holdings, Inc. d.b.a. Bryleos served as the Study Sponsor, providing funding and

maintaining ultimate regulatory responsibility for trial conduct. ISB BioAnalytica Inc. functioned as the

Contract Research Organization, responsible for study design, implementation, and operational

oversight in accordance with ICH GCP guidelines. The Institute for Systems Biology (ISB) provided

scientific collaboration and bioanalytical expertise.

DATA AVAILABILITY

The clinical trial data underlying this study are available from the corresponding author upon reasonable

request, subject to participant privacy protections and institutional data sharing agreements. The

reproducible analysis pipeline code is available at [repository URL to be added prior to publication].

REFERENCES

1.   Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12-9.

2.   Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-13.

3.   Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22(1):31-53.

4.   Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-47.

5.   Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-41.

6.   Katsyuba E, Romani M, Hofer D, Auwerx J. NAD(+) homeostasis in health and disease. Nat Metab. 2020;2(1):9-31.

7.   Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217.

8.   Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-78.

9.   Dutta S. CD38 as a driver of ageing. Nat Rev Endocrinol. 2026;22(3):137.

10.   Camacho-Pereira J, Tarrago MG, Chini CCS, Nin V, Escande C, Warner GM, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-39.

11.   Chini CCS, Peclat TR, Warner GM, Kashyap S, Espindola-Netto JM, de Oliveira GC, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD(+) and NMN levels. Nat Metab. 2020;2(11):1284-304.

12.   Imai SI. NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control. NPJ Aging. 2025;11(1):4.

13.   Hope HC, de Sostoa J, Ginefra P, Andreatta M, Chiang YH, Ronet C, et al. Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Nat Cancer. 2025;6(9):1524-36.

14.   Santiago-Cruz W, Espinosa E, Perez-Lara JC, Romero-Ramirez H, Devarajan P, Garcia-Garcia F, et al. CD38 promotes LPS-induced innate-like activation and proliferation of CD8(+) T lymphocytes in aged mice. Front Aging. 2025;6:1701685.

15.   Clement J, Wong M, Poljak A, Sachdev P, Braidy N. The Plasma NAD(+) Metabolome Is Dysregulated in "Normal" Aging. Rejuvenation Res. 2019;22(2):121-30.

16.   Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.

17.   Chaleckis R, Murakami I, Takada J, Kondoh H, Yanagida M. Individual variability in human blood metabolites identifies age-related differences. Proc Natl Acad Sci U S A. 2016;113(16):4252-9.

18.   Bagga P, Hariharan H, Wilson NE, Beer JC, Shinohara RT, Elliott MA, et al. Single-Voxel (1) H MR spectroscopy of cerebral nicotinamide adenine dinucleotide (NAD(+)) in humans at 7T using a 32-channel volume coil. Magn Reson Med. 2020;83(3):806-14.

19.   Cuenoud B, Ipek O, Shevlyakova M, Beaumont M, Cunnane SC, Gruetter R, et al. Brain NAD Is Associated With ATP Energy Production and Membrane Phospholipid Turnover in Humans. Front Aging Neurosci. 2020;12:609517.

20.   Zhu XH, Lu M, Lee BY, Ugurbil K, Chen W. In vivo NAD assay reveals the intracellular NAD
contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A.
2015;112(9):2876-81.
21.   Migliavacca E, Tay SKH, Patel HP, Sonntag T, Civiletto G, McFarlane C, et al. Mitochondrial
oxidative capacity and NAD(+) biosynthesis are reduced in human sarcopenia across ethnicities. Nat
Commun. 2019;10(1):5808.
22.   Kim LJ, Chalmers TJ, Madawala R, Smith GC, Li C, Das A, et al. Host-microbiome interactions
in nicotinamide mononucleotide (NMN) deamidation. FEBS Lett. 2023;597(17):2196-220.
23.   Shats I, Williams JG, Liu J, Makarov MV, Wu X, Lih FB, et al. Bacteria Boost Mammalian Host
NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. Cell Metab. 2020;31(3):564-79
e7.
24.   Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by
creating a metabolic methylation sink. Nat Chem Biol. 2013;9(5):300-6.
25.   Conze DB, Crespo-Barreto J, Kruger CL. Safety assessment of nicotinamide riboside, a form of
vitamin B(3). Hum Exp Toxicol. 2016;35(11):1149-60.
26.   Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. The efficacy and safety of beta-
nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized,
multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience.
2023;45(1):29-43.
27.   Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized
placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and
lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-53.
28.   Dollerup OL, Chubanava S, Agerholm M, Sondergard SD, Altintas A, Moller AB, et al.
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal
muscle from obese and insulin-resistant men. J Physiol. 2020;598(4):731-54.
29.   Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Moller N, et al. Effects of
Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men
With Obesity. J Clin Endocrinol Metab. 2019;104(11):5703-14.
30.   Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide
Riboside Augments the Aged Human Skeletal Muscle NAD(+) Metabolome and Induces
Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-28 e6.
31.   Pavlech LL, Yoon S, Gianturco SL, Storm KD, Yuen MV, Mattingly AN. Nicotinamide adenine
dinucleotide: Summary Report. University of Maryland Center of Excellence in Regulatory Science and
Innovation; 2021.
32.   Kulikova V, Shabalin K, Nerinovski K, Dolle C, Niere M, Yakimov A, et al. Generation,
Release, and Uptake of the NAD Precursor Nicotinic Acid Riboside by Human Cells. J Biol Chem.
2015;290(45):27124-37.
33.   Nikiforov A, Kulikova V, Ziegler M. The human NAD metabolome: Functions, metabolism and
compartmentalization. Crit Rev Biochem Mol Biol. 2015;50(4):284-97.
34.   Hawkins J, Idoine R, Kwon J, Shao A, Dunne E, Hawkins E, et al. Randomized, placebo-
controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults. medRxiv.
2024:2024.06. 06.24308565.
35.   Saqr AA, Kamali C, Brunnbauer P, Haep N, Koch P, Hillebrandt KH, et al. Optimized protocol
for quantification of extracellular nicotinamide adenine dinucleotide: evaluating clinical parameters and
pre-analytical factors for translational research. Front Med (Lausanne). 2023;10:1278641.

36.   Vinten KT, Tretowicz MM, Coskun E, van Weeghel M, Canto C, Zapata-Perez R, et al. NAD(+)
precursor supplementation in human ageing: clinical evidence and challenges. Nat Metab.
2025;7(10):1974-90.
37.   Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros
and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-308.
38.   Zimmerman M, Kiefer R, Kerr S, Balling C. Reliability and validity of a self-report scale for
daily assessments of the severity of anxiety symptoms. Compr Psychiatry. 2019;90:37-42.
39.   Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the
Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav
Res Ther. 1995;33(3):335-43.
40.   Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration
(D-FIS). Qual Life Res. 2002;11(3):263-72.
41.   Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, et al. Analysis of the adult
human plasma metabolome. Pharmacogenomics. 2008;9(4):383-97.
42.   Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis
program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
43.   Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L.
Erlbaum Associates; 1988. xxi, 567 p. p.
44.   Galwey NW. A new measure of the effective number of tests, a practical tool for comparing
families of non-independent significance tests. Genet Epidemiol. 2009;33(7):559-68.
45.   Brydges CR. Effect Size Guidelines, Sample Size Calculations, and Statistical Power in
Gerontology. Innov Aging. 2019;3(4):igz036.
46.   Chen M, Yuan L, Chen B, Chang H, Luo J, Zhang H, et al. SLC29A1 and SLC29A2 are human
nicotinamide cell membrane transporters. Nat Commun. 2025;16(1):1181.
47.   Gasparrini M, Sorci L, Raffaelli N. Enzymology of extracellular NAD metabolism. Cell Mol
Life Sci. 2021;78(7):3317-31.
48.   Bruzzone S, Guida L, Zocchi E, Franco L, De Flora A. Connexin 43 hemi channels mediate
Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J. 2001;15(1):10-2.
49.   Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Rota R, et al. The differential impact of
three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Nat Metab.
2026;8(1):62-73.
50.   McReynolds MR, Chellappa K, Chiles E, Jankowski C, Shen Y, Chen L, et al. NAD(+) flux is
maintained in aged mice despite lower tissue concentrations. Cell Syst. 2021;12(12):1160-72 e4.
51.   Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of
NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled
Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9(1):9772.
52.   Morifuji M, Higashi S, Ebihara S, Nagata M. Ingestion of beta-nicotinamide mononucleotide
increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a
double-blind randomized, placebo-controlled study. Geroscience. 2024;46(5):4671-88.
53.   Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. Nicotinamide
mononucleotide increases muscle insulin sensitivity in prediabetic women. Science.
2021;372(6547):1224-9.
54.   Ye B, Pei Y, Wang L, Meng D, Zhang Y, Zou S, et al. NAD(+) supplementation prevents
STING-induced senescence in CD8(+) T cells by improving mitochondrial homeostasis. J Cell
Biochem. 2024;125(3):e30522.

55.   Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, et al. N-
methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl. 2003(84):S19-21.
56.   Hikosaka K, Ikutani M, Shito M, Kazuma K, Gulshan M, Nagai Y, et al. Deficiency of
nicotinamide mononucleotide adenylyltransferase 3 (nmnat3) causes hemolytic anemia by altering the
glycolytic flow in mature erythrocytes. J Biol Chem. 2014;289(21):14796-811.
57.   Pospieszna B, Kusy K, Slominska EM, Zielinski J, Ciekot-Soltysiak M. Erythrocyte
nicotinamide adenine dinucleotide concentration is enhanced by systematic sports participation. BMC
Sports Sci Med Rehabil. 2024;16(1):216.
875